# Fujian South Pharmaceutical Co. Ltd · 66-66 · CHINA — FDA import alert red lists: firms subject to detention without physical examination

For Fujian South Pharmaceutical Co. Ltd · 66-66 · CHINA, import alert is 66-66; import alert name is "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"; country is CHINA; product is Paclitaxel; product code is 62 I - - 91 Paclitaxel (Anti-Neoplastic); date published is 08/14/2012; address is Mingxi County , No. 98 Dongxin Road; Xuefengzhen Mingxixian , Sanming, Fujian CHINA, verified against its source on 2026-09-16.

- **Firm:** Fujian South Pharmaceutical Co. Ltd _(verified: appears in the quote below)_
- **Import alert:** 66-66
- **Import alert name:** "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"
- **Country:** CHINA _(verified: appears in the quote below)_
- **Address:** Mingxi County , No. 98 Dongxin Road; Xuefengzhen Mingxixian , Sanming, Fujian CHINA _(verified: appears in the quote below)_
- **Date published:** 08/14/2012 _(verified: appears in the quote below)_
- **Product code:** 62 I - - 91 Paclitaxel (Anti-Neoplastic) _(verified: appears in the quote below)_
- **Product:** Paclitaxel _(verified: appears in the quote below)_

## What the source says

> Fujian South Pharmaceutical Co. Ltd Date Published : 08/14/2012 Mingxi County , No. 98 Dongxin Road; Xuefengzhen Mingxixian , Sanming, Fujian CHINA 62 I - - 91 Paclitaxel (Anti-Neoplastic) Date Published: 08/14/2012 Desc: Paclitaxel

## Source

- https://www.accessdata.fda.gov/cms_ia/importalert_202.html

Last verified: 2026-09-16. Review by: 2026-11-15.
Part of [FDA import alert red lists: firms subject to detention without physical examination](https://referencesource.org/fda-import-alert-red-list/).